GA101 Associated with Better PFS In Phase III Trial Versus Rituximab in CLL
Two Phase II Ibrutinib Studies Presented to EHA Demonstrate Efficacy as a Monotherapy
FDA Approves Gilotrif Tablets in NSCLC, Boehringer Ingelheim’s First Approved Cancer Drug
Study: Ibrutinib Lowers IgM, Bone Marrow Disease Burden
ASCO Recommends Discussing Pharmacological Prevention
Elderly and Younger Patients Have Similar Outcomes Following Radioembolization
Cancer Genome Atlas Researchers Link Cell Metabolism Pathways To Disease Aggressiveness
Statistical Models Determine Stem-Cell Transplant Effectiveness
Phase II Elotuzumab Study Demonstrates 33 Months PFS
Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study
Biomarker Test Outperforms PSA and Gleason Score in Study
NCI CTEP Approved Trials For the Month of July
FDA Approves Implant For Breast Reconstruction
Trending Stories
- Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- No need for a speculum? A new era of HPV screening
- At AACR, Letai announces prevention and screening project for southern Appalachia, describes a future without paylines
There’s “clear evidence that funding is moving and the system is working.” - Forty years after Chernobyl: Little evidence to show that radiation released from the accident increased cancers globally
